Discover our latest news, updates and press releases

JUMET, BELGIUM – January 28, 2021 – Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) delivering customized process development and GMP (Good Manufacturing Practices) manufacturing services for gene therapy and viral vector-based vaccines, announces today that it has acquired the NevoLine™ Upstream manufacturing platform, the latest equipment of Univercells Technologies. Based on principles […]

Athens, Georgia, USA – March 24, 2021 – CyanVac LLC, a vaccine company, announced today that they have selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), for the development and manufacturing of their COVID-19 intranasal vaccine based on a proprietary parainfluenza virus 5 (PIV5) vector. Exothera will be responsible for the fast-track […]

Brussels, Belgium and Dublin, Ireland, May 18, 2021 – Univercells Technologies, a global provider of next-generation biomanufacturing technologies, and the National Institute of Bioprocessing Research and Training (NIBRT) in Dublin, Ireland, have announced a collaboration to address the need for training in cell and gene therapies (CGTs) using next-generation technologies for viral products manufacture. The […]

PORT WASHINGTON, N.Y., July 1, 2021 – Pall Corporation, a global leader in filtration, separation and purification, today announced a new contract worth more than $7M with full-service contract development and manufacturing organization (CDMO) Exothera S.A. The new contract with Pall will establish a suspension-based manufacturing platform of up to 2000L, using a range of […]

Belgium and Guangzhou, China – Univercells Technologies, a provider of novel biomanufacturing technologies for flexible and scalable viral vector production, has formed a worldwide strategic partnership with VectorBuilder, a global leader in vector design, optimization and manufacturing. Univercells Technologies will work with VectorBuilder’s manufacturing center in Guangzhou, China to develop and optimize platform processes using […]

Hamburg, Germany – September 9, 2021– GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for musculoskeletal disorders, today announced that it has contracted Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), to conduct a feasibility study for the development of a large-scale manufacturing process for its osteoarthritis gene […]

Jumet, Belgium – October 27, 2021– Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), today announced that it has appointed Hanna Lesch as Chief Technology Officer. Hanna’s extensive experience in cell and gene therapies will further extend Exothera’s capabilities in designing high-quality, cost-effective viral vector processes tailored to the requirements of its customers’ […]

Quantoom Biosciences S.A. (“Quantoom”), a biotech with the mission to improve access to essential medicines and autonomy in bioproduction through innovation, today announces that they have received grants from the Bill & Melinda Gates Foundation and the Walloon Region of Belgium for an amount of $7.5 million (€ 6.7 million), and $6.4 million (€ 5.7 […]

Belgium and United States – Univercells Technologies, a leading provider of novel biomanufacturing technologies for flexible and scalable viral production, announces today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and hMSC bioprocess systems. This partnership will optimize manufacturing of extracellular vesicles (EVs) using scalable […]

Dessau-Rosslau (Germany), March 1, 2022 – IDT Biologika, a leading Contract Development and Manufacturing Organization (CDMO) specialized in vaccines, gene and immune therapy and oncolytic viruses based in Germany, and Exothera S.A. collaborate to develop a large-scale manufacturing process for viral vector-based vaccines. The feasibility study is focussing on Modified Vaccinia Ankara (MVA) virus as […]